Skip to main content

Eone-Diagnomics, Cordlife Ink NIPT Deal

NEW YORK (GenomeWeb) – Eone-Diagnomics Genome Center (EDGC) announced today that it has signed an agreement to offer its Gen Screen non-invasive prenatal test in certain Asian markets in partnership with cord blood service provider Cordlife.

Under the terms of the deal, EDGC — joint venture between San Diego-based bioinformatics firm Diagnomics and South Korea's Eone Life Science Institute — will service the test in the Philippines and Indonesia through Singapore-based Cordlife's sales networks in those nations. EDGC said it anticipates expanding the relationship later to include additional Asian countries and its other products such as the DTC genetic test Gene2me and the ophthalmology genetic test Myeyegene.

Additional terms were not disclosed.

Earlier this year, EDGC partnered with Chinese genetic analysis company GPBio to develop and expand consumer and clinical genomic services for Asian markets.